Plasma Fractionation Market Size Projected to Generate a Revenue of $56,870.10 Million by 2031Download Sample Reports Overview
The Global Plasma Fractionation Market Size is predicted to be valued at $56,870.10 million by 2031, surging from $28,194.40 million in 2021, at a noteworthy CAGR of 7.2%.
Impact Analysis of COVID-19 on the Plasma Fractionation Market
The COVID-19 pandemic has had a significant impact on the plasma fractionation market. Plasma fractionation is the process of separating different components of blood plasma, such as albumin, immunoglobulins, and clotting factors, for use in various medical therapies. These therapies include treatments for immune deficiencies, bleeding disorders, and autoimmune diseases. Major impact of COVID-19 on the plasma fractionation market has been the disruption of the global supply chain. The pandemic has caused disruptions in the transportation & logistics of plasma & plasma-derived products, leading to supply shortages and increase in demand. This has resulted in higher prices for plasma-derived products and increase in competition for available supply. The pandemic has led to increase in demand for immunoglobulin products, which are used in the treatment of COVID-19. This has resulted in a shortage of these products, which has further increased their cost. Moreover, the pandemic has led to decrease in demand for certain plasma-derived products, such as albumin, which are used in elective surgeries that were postponed due to COVID-19 impact on plasma fractionation market. Thus, the COVID-19 pandemic has had a significant impact on the plasma fractionation market, leading to supply shortages, increase in demand for certain products, and changes in pricing dynamics.
Global Plasma Fractionation Market Analysis
Increase in demand for plasma-derived products is one of the major drivers of the plasma fractionation market. Plasma-derived products are used for the treatment of a variety of diseases such as immune deficiencies, hemophilia, and liver cirrhosis. Thus, increase in incidence of chronic diseases and growth in aging population are the key factors driving the demand for plasma-derived products. Moreover, increase in use of plasma-derived products in the pharmaceutical industry for the production of vaccines and other therapeutics contributes to the growth of the plasma fractionation market. In addition, advancements in technology and development of new therapies are contributing to the growth of the plasma fractionation market. As new products & treatments become available, the demand for plasma-derived products is likely to continue to rise. These are the major factors anticipated to boost the plasma fractionation market size during the analysis timeframe.
However, the high costs associated with plasma fractionation can indeed restrain the growth of the market, particularly in developing countries or regions with limited healthcare resources. Moreover, the high cost of plasma-derived products can make them unaffordable for many patients, even in developed countries with robust healthcare systems. This can limit access to life-saving treatments, particularly for rare diseases requiring specialized therapies that can hamper the plasma fractionation market growth.
Rise in threat of communicable diseases such as influenza, coronavirus, and HIV will drive demand for plasma fractionation products. The World Health Organization (WHO) reports that the number of reported cases of communicable diseases such as HIV, malaria, and tuberculosis has been steadily increasing over the last few decades. As a result, more efficient & effective treatments & therapies for these diseases are required, which is expected to drive demand for plasma fractionation products in the coming years. Furthermore, the Centers for Disease Control and Prevention (CDC) reports that the risk of emerging and re-emerging diseases, caused by pathogens that have rapidly adapted to their environment, is increasing. This has boosted demand for high-quality plasma fractionation products, which can aid in the prevention and treatment of such diseases. Furthermore, rise in demand for plasma fractionation products used in the production of biopharmaceuticals & vaccines is expected to boost the plasma fractionation market opportunity.
Global Plasma Fractionation Market, Segmentation
The global plasma fractionation market is segmented on the basis of product, application, end user, and region.
The product segment is further classified into immunoglobulin, albumin, coagulation factors, protease inhibitors, and others. Among these, the immunoglobulin subsegment accounted for a dominant plasma fractionation market share in 2021. This growth is attributed to the fact that global demand for plasma-derived therapies has increased significantly. Immunoglobulin demand increased significantly, resulting in positive global market growth. Rise in cases of various immunodeficiency disorders globally is driving up the plasma fractionation products’ demand. A group of 300 diseases known as primary immunodeficiency are characterized by recurrent chronic infections, autoimmunity, allergy, or inflammation. These infections are caused by genetic changes that affect the immune system. Immunoglobulin substitution or specific immunoglobulin therapies can be used to treat such disorders. As a result of growth in demand for such treatments, these processes produce more immunoglobulin, driving the market.
The application segment is further classified into neurology, immunology, hematology, critical care, rheumatology, pulmonology, and others. Among these, the neurology subsegment accounted for a dominant plasma fractionation market share in 2021. This growth is driven by increase in prevalence of neurological disorders such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease. These disorders require long-term treatment with immunoglobulins and other plasma-derived products to manage symptoms and slow disease progression. In addition, there is growth in demand for plasma-derived products for the treatment of autoimmune diseases, such as Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), which affect the peripheral nervous system. Thus, increase in prevalence of neurological disorders, growth in demand for plasma-derived products for autoimmune diseases, and aging population are the key drivers of the neurology segment of the plasma fractionation market growth.
The end user segment is further classified into hospitals & clinics, clinical research laboratories, and academic institutes. Among these, the hospitals & clinics subsegment accounted for a dominant market share in 2021. This growth is attributed to increase in demand for plasma-derived products for the treatment of various diseases. Hospitals & clinics are the primary end users of plasma-derived products, as they are responsible for the diagnosis & treatment of patients with these conditions. As the prevalence of these diseases continues to rise, the demand for plasma-derived products is expected to increase, driving the growth of the segment.
The plasma fractionation market analysis in Asia-Pacific is projected to show the fastest growth. Asia-Pacific has a large population, which means there is higher demand for plasma-derived products; as a result, there is greater need for plasma fractionation. The region has been investing heavily in healthcare infrastructure, which has led to increase in the number of hospitals & healthcare facilities. This has created larger market for plasma fractionation products. Asia-Pacific has seen rise in the incidence of chronic diseases such as cancer, hemophilia, and immune deficiencies. Plasma-derived products are used to treat these conditions, which has led to increase the demand for plasma fractionation. Governments in Asia-Pacific have been taking steps to promote the development of the healthcare industry. This has created more conducive environment for the plasma fractionation market demand.
Key Players in the Global Plasma Fractionation Market
Some of the leading plasma fractionation market players are
- Kedrion S.P.A
- Octapharma AG
- Japan Blood Products Organization
- Biotest AG
- Grifols S.A
- China Biologic Products Holdings Inc
- Takeda Pharmaceutical Company Limited
- Bio Products Laboratory Ltd
- LFB Group
Takeda Pharmaceutical Company Limited acquired Shire Plc in 2022. This acquisition will broaden Takeda’s product portfolio, enabling the company to expand its presence in the plasma fractionation market.